This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News for OVID
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
Other News for OVID
Buy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial Outlook
Wedbush Remains a Buy on Ovid Therapeutics (OVID)
Buy Rating Affirmed for Ovid Therapeutics Amid Strong Clinical Progress and Promising Neurological Pipeline
Buy Rating Justified by Ovid Therapeutics’ Clinical Progress and Strong Financials
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024